ReviewAnnals of the rheumatic diseases2002
Anti-tumour necrosis factor alpha therapy for ankylosing spondylitis: international experience.
Review in Annals of the rheumatic diseases, 2002. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 65 citations in OpenAlex.
- Population pharmacokinetics of rhTNFR-Fc in healthy Chinese volunteers and in Chinese patients with Ankylosing spondylitis.Acta pharmacologica Sinica · 2010Trial
- Magnetic resonance imaging guided corticosteroid injection of sacroiliac joints in patients with spondylarthropathy. Are multiple injections more beneficial?Rheumatology international · 2006Trial
- Outcomes of a multicentre randomised clinical trial of etanercept to treat ankylosing spondylitis.Annals of the rheumatic diseases · 2004Trial
- Efficacy of anakinra in active ankylosing spondylitis: a clinical and magnetic resonance imaging study.Annals of the rheumatic diseases · 2004Trial
- Influence of TNF-α Inhibitors on Gut Microbiota and Immune Modulation in Treating Ankylosing Spondylitis: Insights into Therapeutic Mechanisms and Clinical Implications.Journal of inflammation research · 2024Article
- Sixteen syndrome: a rare presentation of central demyelination.BMJ case reports · 2023Article
- The Journey to Diagnose Spondyloarthritis in Patients From Riyadh: A Cross-Sectional Study.Cureus · 2022Article
- Lessons on SpA pathogenesis from animal models.Seminars in immunopathology · 2021Review
- Randomized Cross Over Study Assessing the Efficacy of Non-invasive Stimulation of the Vagus Nerve in Patients With Axial Spondyloarthritis Resistant to Biotherapies: The ESNV-SPA Study Protocol.Frontiers in human neuroscience · 2021Article
- Enhanced NETosis generation in radiographic axial spondyloarthritis: utility as biomarker for disease activity and anti-TNF-α therapy effectiveness.Journal of biomedical science · 2020Article
- Anti-TNF Therapy in Spondyloarthritis and Related Diseases, Impact on the Immune System and Prediction of Treatment Responses.Frontiers in immunology · 2019Review
- Atherosclerosis and endothelial dysfunction in patients with ankylosing spondylitis.Rheumatology international · 2010Review
- Etanercept in the treatment of rheumatoid arthritis: clinical follow-up over one year by ultrasonography.Clinical rheumatology · 2008Article
- Diagnosis delay in patients with ankylosing spondylitis: possible reasons and proposals for new diagnostic criteria.Clinical rheumatology · 2008Article
- Pulmonary involvement in ankylosing spondylitis.Clinical rheumatology · 2007Article
- How to diagnose axial spondyloarthritis early.Annals of the rheumatic diseases · 2004Article
- Cytokines in the seronegative spondyloarthropathies and their modification by TNF blockade: a brief report and literature review.Annals of the rheumatic diseases · 2003Review
- Does etanercept induce uveitis?The British journal of ophthalmology · 2003Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 8 institutions in 7 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The conventional approach to treatment of patients with spondyloarthritis (SpA), particularly ankylosing spondylitis (AS), has serious limitations, adding a sense of urgency to the evaluation of new treatments for these rheumatic disorders. Tumour necrosis factor alpha (TNFalpha) is a cytokine that has been shown to mediate inflammatory and regulatory activities in SpA and other immune mediated diseases, including other arthritides and inflammatory bowel disease. Positive results have been reported in several international open label and randomised controlled trials of infliximab and etanercept, the two main biological agents targeting TNFalpha, which have included approximately 300 patients with SpA. Specifically, TNFalpha-directed therapy resulted in significant improvements in disease activity, function, and quality of life in these patients, most of whom had AS and received infliximab. Preliminary evidence from open label, long term extension trials suggests clinical benefit with continued use. Serious side effects were rare and consistent with experience from patient groups receiving infliximab or etanercept treatment for inflammatory bowel disease or rheumatoid arthritis. Together, these findings herald an age of more effective treatment of patients with AS with anti-TNFalpha and other emerging biological agents.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.